Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Ligand Pharmaceuticals (LGND) Receivables - Other: 2017-2018

Ligand Pharmaceuticals' Receivables - Other was N/A to $8.0 million in Q4 2018 from the same period last year, while for Dec 2018 it was $8.0 million, marking a year-over-year change of. This contributed to the annual value of $8.0 million for FY2018, which is N/A change from last year.
Per Ligand Pharmaceuticals' latest filing, its Receivables - Other stood at $8.0 million for Q4 2018, which was up 60.00% from $5.0 million recorded in Q3 2017.
Ligand Pharmaceuticals' 5-year Receivables - Other high stood at $8.0 million for Q4 2018, and its period low was $5.0 million during Q2 2017.
Its 2-year average for Receivables - Other is $6.0 million, with a median of $5.0 million in 2017.